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Dengue virus (DENV) is a human arboviral pathogen
accounting for 390 million infections every year.
The available vaccine has limited efficacy, and
DENV-specific drugs have not been generated. To
better understand DENV-host cell interaction, we
employed RNA interference-based screening of the
human kinome and identified fibroblast growth factor
receptor 4 (FGFR4) to control the DENV replication
cycle. Pharmacological inhibition of FGFR exerts a
reciprocal effect by reducing DENV RNA replication
and promoting the production of infectious virus par-
ticles. Addressing the latter effect, we found that the
FGFR signaling pathway modulates intracellular
distribution of DENV particles in a PI3K-dependent
manner. Upon FGFR inhibition, virions accumulate
in the trans-Golgi network compartment, where
they undergo enhanced maturation cleavage of
the envelope protein precursor membrane (prM),
rendering virus particles more infectious. This study
reveals an unexpected reciprocal role of a cellular
receptor tyrosine kinase regulating DENV RNA repli-
cation and the production of infectious virions.
INTRODUCTION
Dengue fever, hemorrhagic fever, and shock syndrome caused
by infection with the dengue virus (DENV) are among the most
prevalent arbovirus-associated diseases globally. According toCell
This is an open access article undtheWorld Health Organization (WHO), around 40%of theworld’s
population lives in areas endemic to this disease, with DENV
causing around 100 million symptomatic infections and more
than 20,000 deaths annually (Bhatt et al., 2013). In the absence
of clinically approved drugs, treatment of DENV infections is
only symptomatic. The existence of four antigenically distinct
serotypes (DENV1–DENV4) and antibody-dependent enhance-
ment (ADE) exacerbating secondary infection with a heterolo-
gous serotype have hindered the development of an effective
prophylactic vaccine (Acosta and Bartenschlager, 2016).
The genome of DENV is a single-strand RNA of positive
polarity. The genome encodes for a polyprotein that is co- and
post-translationally cleaved into three structural and seven
nonstructural proteins. The latter contribute to the establishment
of endoplasmic reticulum (ER)-associated viral replication organ-
elles, where the DENV genome is amplified. The structural
proteins capsid (C), precursor membrane (prM), and envelope
(E), together with one copy of the progeny RNA genome, form
the nucleocapsid that acquires its lipid E by budding into the
ER lumen. Assembled particles can often be observed as an
ordered array in the ER before transport to the Golgi apparatus
and subsequent secretion via the conventional secretory
pathway. During this transport, maturation of DENV virions oc-
curs via cleavage of prM within the trans-Golgi network (TGN)
by the TGN-resident protease furin (for a detailed description of
the viral replication cycle, seeNeufeldt et al., 2018). This cleavage
is essential to render DENV particles infectious.
Signaling cascades induced by both endogenous and exoge-
nous stimuli influence the secretory pathway and modulate its
function and organization (reviewed in Farhan and Rabouille,
2011). Key players of intracellular signaling are kinases and
phosphatases. It has been suggested that more than 100 cellularReports 27, 2579–2592, May 28, 2019 ª 2019 The Author(s). 2579
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
kinases and phosphatases are involved in the regulation and
organization of the secretory pathway (Farhan et al., 2010).
The fibroblast growth factor receptor (FGFR) family of recep-
tor tyrosine kinases comprises 4 highly conserved members
whose signaling cascade influences several aspects of cellular
homeostasis, including cell growth, proliferation, differentia-
tion, and survival (Ornitz and Itoh, 2015). Binding of the ligand,
fibroblast growth factor (FGF), induces receptor activation
through dimerization and subsequent auto-phosphorylation.
The main substrates of FGFR phosphorylation are phosphoino-
sitide phospholipase Cg (PLC-g) and FGF receptor substrate 2a
(FRS2a). FRS2a phosphorylation is required for downstream
signaling through the phosphatidylinositol 3-kinase (PI3K)-
AKT and the RAS-mitogen-activated protein kinase (MAPK)/
extracellular signal-regulated kinase (ERK) pathways.
Like all other viruses, DENV extensively exploits host cell path-
ways at all steps of its replication cycle. The recently reported
high-throughput RNA interference and CRISPR-Cas9-based
screens, together with proteomic studies, revealed numerous
host cell pathways and proteins essential for the viral replication
cycle and pathogenesis of flaviviruses (Scaturro et al., 2018;
Marceau et al., 2016; Zhang et al., 2016; Savidis et al., 2016;
Hafirassou et al., 2017; Chatel-Chaix et al., 2016). These include
essential housekeeping genes associated with viral RNA transla-
tion; polyprotein processing, e.g., by the signal peptidase (Zhang
et al., 2016); and viral protein modification, e.g., by the oligosac-
charyltransferase complex (Marceau et al., 2016). Additional
host cell factors affecting the flaviviral replication cycle by un-
known mechanisms have been reported, such as the cytosolic
chaperonin-containing T complex (Hafirassou et al., 2017) and
several mitochondrial proteins (Chatel-Chaix et al., 2016).
In the present study, we screened the human kinome using an
RNAi-based approach to identify host cell kinases that are
required for enhancing or suppressing DENV replication. Among
these proteins, we identified FGFR4 as a kinase playing a recip-
rocal role in the DENV life cycle by promoting RNA replication but
suppressing the production of infectious virus particles. The latter
effect was mapped to a PI3K-dependent signaling pathway
increasing the specific infectivity by enhanced maturation cleav-
age of prM, most likely as a result of altered intracellular traf-
ficking of DENV particles.
RESULTS
Identification of Cellular Kinases Involved in DENV
Replication via an RNAi-Based Screen
To identify kinases involved in DENV replication, high-throughput
small interfering RNA (siRNA)-based screening of the human
kinome was performed. The primary screening consisted of an
automated, image-based, high-content assay using a library
containing siRNAs targeting 719 cellular kinases. Each kinase
was targeted with three independent siRNAs, alongside positive
control siRNAs directed against DENV NS1 or NS3 regions of the
genome and nontargeting negative controls (Figure 1A). Huh7
cells were reverse transfected on cell arrays with siRNAs for
48 h, infected with DENV2 New Guinea C (NGC) strain for 24 h,
fixed, and processed for immunofluorescence analysis using an
E-specific antibody (Figure 1A). Nuclear DNA was stained with2580 Cell Reports 27, 2579–2592, May 28, 2019DAPI and used to calculate the total number of cells in a given
spot area (Figure 1B). Host dependency factors (HDFs), i.e., fac-
tors that facilitate viral replication, were considered relevant when
a Z score cutoff of %1 and a p value of <0.05 were obtained;
host restriction factors (HRFs), i.e., factors that impair viral repli-
cation, were pursued when a Z score cutoff ofR+1 and a p value
of <0.05 were reached, eachwith at least one siRNA. Using these
criteria, 60 potential HDFs and 50 potential HRFs were selected
for the validation screen (Figure 1C; Table S1). For this, three
independent siRNAs from a different supplier were used to mini-
mize off-target effects, and a Renilla-luciferase reporter virus
(DV-R2A) (Fischl and Bartenschlager, 2013) derived from the
DENV2 (16681 strain) was used to identify hits common between
various DENV strains (Figure 1D). The analysis of the validation
screen data indicated a robust performance of control siRNAs
and a high correlation (Pearson correlation coefficient R 0.8)
between the replicates. Using a Z score cutoff of %2 for
HDFs and R+2 for HRFs and p % 0.05, we defined 19 HDFs
and 15 HRFs (Figure 1E; Table S2).
DENV Infection Modulates the FGFR Signaling Pathway
Among the HDFs identified in this kinome screen, knockdown of
FGFR4 showed a robust reduction of viral replication. For this
reason, and because of the availability of inhibitors and genetic
tools to study the FGFR signaling pathway, we selected this hit
for further characterization. First, we assessed whether DENV
infection modulates the FGFR signaling pathway (Figure 2A) by
analyzing the relative abundance of basal and phosphorylated
FGFR4, as well as downstream signaling molecules, using west-
ern blotting (Figure 2B). While phosphorylation levels of FGFRs
were not significantly altered during the course of infection (Fig-
ure 2C, upper left panel), a strong reduction in the amounts of
FGFR4 was observed at the late stage of infection (Figure 2C,
top right panels). In contrast, the amount of ERK1/2 protein
and its phosphorylation status did not change during this time
span, arguing against general DENV-induced degradation of
cellular kinases. The decrease in total FGFR4 levels was accom-
panied by a reduction of pFRS2a, suggesting inhibition of the
downstream signaling cascade (Figure 2C, middle left panel).
Although the decrease of FGFR4 abundance during the course
of the infection is an unexpected feature for a HDF, our results
indicate that DENV modulates the FGFR signaling pathway.
Pharmacological Inhibition of the FGFR Pathway
Suppresses DENV RNA Replication and Enhances
Infectious Virus Production in a PI3K-Dependent
Manner
To gain insights into the role of FGFR in the DENV life cycle, we
measured viral replication upon pharmacological inhibition of
different steps of the FGFR signaling pathway (Figure 3A). For
this purpose, we used the FGFR inhibitor PD173074. Treatment
of Huh7 cells with noncytotoxic concentrations of the compound
robustly downregulated the FGFR signaling pathway, as re-
vealed by the reduction in the phosphorylation levels of the
downstream kinases FRS2a and ERK1/2 (Figures S1A and
S1B). To determine whether the FGFR pathway plays a role in
DENV entry or RNA replication, which could not be discriminated
in our RNAi-based screening assay, we used a subgenomic
Figure 1. RNAi-Based Screening for Human
Kinases Involved in the DENV Life Cycle
(A) Schematic representation of the primary ki-
nome screen. Huh7 cells were reverse transfected
on cell arrays with three independent siRNAs per
gene, targeting in total700 cellular kinases. After
48 h, cells were infected with the DENV2 NGC
strain (MOI = 5), harvested 24 h post-infection, and
processed for immunofluorescence assay. DENV
replication was measured by immunostaining
against E protein.
(B) Representative images of immunostaining of
positive and negative controls (a siRNA targeting
NS1 and a scrambled siRNA, respectively). The
envelope signal is depicted in red; nuclei is de-
picted in blue. The yellow circle indicates the area
where the transfection mixture had been spotted.
(C) Results of the primary siRNA screen. The mean
Z score of each siRNA is displayed in gray. Mean
Z scores of negative and positive controls
(scrambled siRNA and siRNA directed against
Envelope and NS3, respectively) are shown in blue
and red, respectively. The hit selection criteria
(1 > z > 1; p < 0.05) are indicated by the blue and
red lines, respectively. Potential host dependency
factors (HDFs) and host restriction factors (HRFs)
are highlighted in light green and light blue,
respectively.
(D) Setup of the validation screen. Huh7 cells were
reverse transfected using three siRNAs per gene.
A total of 110 primary hits were included. Forty-
eight hours after transfection, cells were infected
with the DV-R2A Renilla luciferase reporter virus.
Viral replication was measured 48 h later by lucif-
erase assay.
(E) List of the top five potential HDFs and HRFs
from the validation screen.
See also Tables S1 and S2.reporter replicon that was electroporated into Huh7 cells, thus
bypassing the entry step. Different concentrations of the FGFR
inhibitor were added immediately after electroporation, and viral
replication was measured after 48 h (Figure S1C). A consistent
reduction of viral RNA replication was observed. Although the
magnitude of inhibition was rather low, a stronger reduction of
DENV replication was found when we used infection of Huh7
cells, allowing pretreatment of the cells with the compound,
which was not possible in the electroporation setting (Figure 3B).
Time of addition experiments using trans-complemented parti-
cles, which allow only single-round infection (Scaturro et al.,
2014), showed that the inhibitory effect was stronger when the
compound was added before or right after infection. The inhibi-
tory effect was gradually lost when the compound was added
later during infection (Figure S1D). This kinetic argues for a role
of FGFR signaling in an early step during the DENV infectionCellcycle, such as viral RNA translation or the
establishment of the membranous replica-
tion organelle.
Although replication was suppressed,
the amount of infectious virus particles
released from infected cells treated with
the FGFR inhibitor increased up to 12-fold, indicating a reciprocal effect of FGFR signaling inhibition
on DENV RNA replication and virus production (Figure 3C). In
agreement with these results, activation of the FGFR signaling
pathway by overexpression of the cognate FGFR ligand FGF19
increased viral replication but significantly reduced the produc-
tion of infectious virus particles (Figures 3D and 3E, respectively).
Cotreatment of FGF19-overexpressing cells with the FGFR in-
hibitor PD173074 blunted these effects, confirming the speci-
ficity of the compound (Figures 3D and 3E).
Observed phenotypes were not limited to DENV2 isolates,
because FGFR inhibition increased extracellular infectivity of all
DENV serotypes, as well as two strains of the Zika virus (ZIKV;
MR766 and H/PF/2013) (Figures 3F and 3G). Conversely, no sig-
nificant effects were observed with the related West Nile virus
and Rift Valley Fever Virus (RVFV), a negative-strand RNA virus
belonging to the Phenuiviridae family (Figure 3G and S1E,Reports 27, 2579–2592, May 28, 2019 2581
(legend on next page)
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Figure 3. Pharmacological Inhibition of
FGFR Reduces DENV Replication and
Increases Virus Production
(A) Schematic illustration of the FGFR4 pathway.
Targets of used inhibitors and agonists are indi-
cated.
(B and C) Huh7 cells were treated for 16 h with
PD173074 before infection with DV-R2A. After
48 h, replication was quantified by luciferase assay
(B), and amounts of infectious virus were deter-
mined by plaque assay (C). The inhibitor was pre-
sent throughout the experiment.
(D) Agonization of FGFR4 by FGF19 enhances
DENV replication. Huh7 cells were transfectedwith
a construct encoding FGF19, treated 16 h later
with either DMSO or PD173074 (0.6 mM), and in-
fected 8 h later with the DENV reporter virus. After
72 h, replication levels were measured by lucif-
erase assay.
(E) Agonization of FGFR4 by FGF19 reduces DENV
virion production. Cells were treated as in (D), and
titers of the DENV reporter virus contained in the
cell culture supernatant 72 h after infection were
measured by plaque assay.
(F and G) Huh7 cells were pretreated for 16 h with
0.6 mM of PD173074 before infection with the
indicated viruses (MOI = 0.1). After 72 h (F) or 48 h
(G), titers were quantified by plaque assay.
(H and I) DENV replication and virus production
in Huh7 cells pretreated with the PI3K inhibitor
LY294002 or the MEK1/2 inhibitor U0126. Huh7
cells were treated overnight with indicated
concentrations of the drugs, infected with DV-
R2A (MOI = 1), and harvested 48 h later. Repli-
cation was measured by luciferase assay (H),
whereas virus titers were quantified by plaque
assay (I).
Mean and SD of two (H and I) or three (B–G)
independent experiments are shown. Student’s
t test was used to analyze the data, except for
(B) and (C), where data were analyzed with
one-way ANOVA and Dunnett’s post hoc test. *p <
0.05; **p < 0.01; ***p < 0.001. See also Figure S1.respectively). These results suggest that FGFR signaling plays a
critical role in the life cycle of all DENV serotypes, aswell as some
closely related flaviviruses such as ZIKV.
The FGFR signaling cascade branches through two main
pathways: theMAPK pathway and the PI3K pathway (Figure 3A).
To determine the effect of each pathway on DENV infectivity, we
used LY294002 and U0126, two inhibitors targeting PI3K or
MEK1/2, which is directly upstream of ERK, respectively (Fig-
ure 3A). Inhibition of the PI3K pathway with LY294002 mirroredFigure 2. DENV Infection Modulates the FGFR Signaling Pathway
(A) Schematic of the FGFR4 signaling pathway. Kinases analyzed by western b
GRB2-associated-binding protein 1; PLCg, phosphoinositide phospholipase Cg
bound protein 2; STAT3, signal transducer and activator of transcription 3; PKC,
(B) Huh7 cells were left untreated or infectedwith DENV2 (16681 strain;MOI = 5) an
to the right of each panel were determined by western blot. NS3 and GAPDH we
(C) Levels of proteins specified at the top of each panel and detected by wes
expressed as mean and SD from at least three independent experiments.
Data were analyzed using Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.the effects of FGFR inhibition, because it significantly reduced
viral replication and increased the amount of released infectious
virus (25-fold; p < 0.05) (Figures 3H and 3I, respectively).
Conversely, inhibition of MEK1/2 affected viral replication only
to a minor extent and had no significant effect on virus produc-
tion (Figures 3H and 3I, respectively). For both compounds, no
effect on cell viability was observed with used drug concentra-
tions (Figure S1F). The effect of FGFR and PI3K pathway inhibi-
tion on DENV replication and infectivity was validated in 293Tlot are highlighted in brown. FRS2a, fibroblast receptor substrate 2a; GAB1,
; JAK, Janus kinase; SOS, son of sevenless; GRB2, growth factor receptor-
protein kinase C; PI3K, phosphatidylinositol 3-kinase.
d harvested at the indicated time points. Expression levels of proteins specified
re used as infection and loading controls, respectively.
tern blot were quantified using the ImageJ software package. All values are
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Figure 4. Enhanced FGFR4 Signaling by
Overexpression of Constitutively Active Mu-
tants Reduces the Production of Infectious
DENV Particles
Huh7 cells were transduced with lentiviruses
encoding indicated FGFR proteins. Three days
post-transduction (dpt), cells were infected with
the DV-R2A (MOI = 1).
(A) Western blots were performed 3 dpt using
lysates of transduced cells. Numbers below the
lanes correspond to the ratio between phospho-
and total protein normalized to the empty control
sample (a lentivirus encoding no heterologous
protein). A representative experiment of three
independent repetitions is shown.
(B) Viability of Huh7 cells as determined by mea-
surement of ATP levels 6 days after transduction
with lentiviruses encoding the indicated proteins.
Means and SD from 3 technical replicates are
shown.
(C) Viral replication was measured by luciferase
reporter assay. Means and SD from triplicate
samples are shown. Data were analyzed using
Student’s t test.
(D) Virus titers as determined by plaque assay.
Means and SD from triplicate samples are dis-
played. Data were analyzed using Student’s t test.
*p < 0.05; **p < 0.01; ***p < 0.001.cells and gave phenotypes similar to those observed in Huh7
cells (Figures S1G–S1I). Altogether, these results suggest that in-
hibition of the FGFR pathway via the PI3K branch is responsible
for the reciprocal effect on DENVRNA replication and production
of infectious virus particles.
Activation of FGFR4 Signaling by Constitutively Active
Mutants Reduces Infectious DENV Particle Production
To corroborate our findings, we modulated FGFR signaling with
a drug-independent strategy by overexpression of two constitu-
tively active mutants of this receptor tyrosine kinase: the K645E
mutant carrying an amino acid substitution in the kinase auto-in-
hibition loop and the FGFR4 Y367C mutant containing an addi-
tional cysteine residue in the extracellular region that induces
spontaneous dimerization and receptor activation (Webster
and Donoghue, 1996; Ruhe et al., 2007). Empty vector was
used as control. To avoid pleiotropic effects resulting from pro-
longed overexpression, cells were transduced with lentiviruses,
and signaling activation was assessed three days later by west-
ern blot analysis using phospho-specific antibodies. Expression
of both constitutively active receptors increased the phosphory-2584 Cell Reports 27, 2579–2592, May 28, 2019lation levels of FRS2a and ERK1/2 ki-
nases, with no effects on cell viability (Fig-
ures 4A and 4B, respectively).
Having confirmed the activities of these
FGFR mutants, cells were infected with
the DENV reporter virus 3 days after lenti-
viral transduction, and viral replication
and virus production were measured 48
and 72 h after infection using luciferase
reporter and plaque assay, respectively(Figures 4C and 4D). At 48 h post-infection, stimulation of the
FGFR signaling pathway via expression of both constitutively
activemutantsmirrored the results obtainedwith ligand-induced
receptor activation (FGF19), with an increase in viral replication
and a reduction in titers of infectious virus infectivity (Figures
4C and 4D). Extracellular infectivity decreased further 72 h
post-infection and was around 17-fold lower in the case of the
K645E mutant compared with empty vector-transduced cells.
Consistently, at the same time point, viral replication in the cul-
ture decreased up to around 2-fold, probably due to a reduction
in viral spread caused by the decreased virus titer.
These results show that activation of the FGFR pathway,
through overexpression of constitutive active FGFR4, reduces
the production of infectious DENV particles, consistent with
data obtained by pharmacological inhibition of the FGFR4
signaling pathway.
FGFR Inhibition Enhances Specific Infectivity
The increased infectivity titers observed upon FGFR inhibition
suggested increased assembly, enhanced virus release, or
higher infectivity of released particles. To test for an effect on
Figure 5. FGFR Inhibition Enhances the Specific Infectivity of Virus Particles
(A) Huh7 cells transfected with Gaussia luciferase reporter plasmid were treated with the indicated concentrations of PD173074 for 72 h. Gaussia luciferase
activity was quantified by luciferase assay. Ratios between extra- and intracellular luciferase values are given.
(B) Huh7 cells were treated with the indicated inhibitors and infected with DENV for 72 h. Compounds were present throughout the experiment. Virus titers within
cells were determined following repeated freeze-thaw cycles; extracellular virus titers were determined using culture supernatants. Values were normalized to
DMSO-treated control cells.
(C) Intra- and extracellular amounts of DENV capsid and prM proteins after treatment of Huh7 cells with the indicated inhibitors for 72 h. Lower panels show
representative western blots, and upper panels display the quantification of the protein signals.
(legend continued on next page)
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particle release, we analyzed the impact of FGFR pathway inhi-
bition on conventional secretion, which is the main secretory
route used by DENV (Neufeldt et al., 2018). No changes of the
secretion of a transiently expressed secreted version of a Gaus-
sia luciferase were observed upon treatment with PD173074
(Figure 5A), suggesting that FGFR pathway inhibition does not
affect secretion through the conventional secretory route. This
finding, together with the observed increase in both intra- and
extracellular infectivity upon FGFR4 inhibition (Figure 5B), rules
out an effect of FGFR signaling on DENV particle release and
argues for enhanced virion assembly or specific infectivity.
However, treatment with the FGFR4 or PI3K inhibitor did not
affect intra- and extracellular amounts of DENV C protein (Fig-
ure 5C), arguing against an increase of DENV particle assembly.
Consistently, amounts of extracellular viral RNA were unaltered
(Figure 5D) even though extracellular infectivity was increased
(Figure 5B), indicating enhanced infectivity of DENV particles
released from FGFR inhibitor-treated cells. Calculation of the
ratio between extracellular virus titers and viral genomes (reflect-
ing the number of released particles) supported this conclusion
(Figure 5E). Consistently, activation of the signaling pathway by
overexpression of constitutive active FGFR4mutants decreased
the specific infectivity of released particles (Figure 5F). These
results provide strong evidence that FGFR plays an important
role in DENV particle infectivity. In addition, the observation
that the amount of extracellular prM was reduced indicated a
qualitative change of the virions (Figure 5C).
FGFR Signaling Alters Intracellular Distribution of
Assembled DENV Particles
Next, we sought to identify the molecular mechanism linking
FGFR to the specific infectivity of DENV particles. Because
FGFR signaling modulates cholesterol homeostasis and fatty
acid biosynthesis (Ornitz and Itoh, 2015), modulation of this
signaling pathway might alter the lipid composition of the virus
particles, thus influencing their stability and infectivity. However,
no changes in particle stability were observed upon either phar-
macological inhibition or stimulation of the FGFR pathway, as
measured by the resistance of infectious DENV particles to tem-
perature increases or repeated freeze-thaw cycles (Figure S2).
Virus particle infectivity is tightly linked to the maturation step,
which occurs in the TGN compartment and involves furin-medi-
ated cleavage of prM to generate a mature membrane (M) pro-
tein (Neufeldt et al., 2018). Although modulation of the FGFR
signaling pathway affected neither furin protein levels (Figures
S3A and S3B) nor furin activity (Figures S3C and S3D), increased
colocalization between prM and TGN marker TGN46 was
observed, which was most evident 48 h post-infection (Figures
6A and 6B). This subcellular localization argued for altered intra-
cellular trafficking of DENV particles, with prolonged accumula-
tion in the TGN upon PD173074 and LY294002 treatments.
Therefore, we visualized intracellular particle distribution more(D) Quantitation of DENV RNA associated with extracellular virions using qRT-PC
(E) Specific infectivity of DENV particles calculated as the ratio of infectious titers
(F) Specific infectivity of virus particles released 72 h post-infection from cells ex
Means and SD from three independent experiments are shown. Data were analyze
*p < 0.05; **p < 0.01; ***p < 0.001.
2586 Cell Reports 27, 2579–2592, May 28, 2019precisely using electron microscopy analysis of infected cells
treated with FGFR or PI3K inhibitors (Figure 6C). Although we
could not discriminate between mature and immature particles
due to resolution limits, quantification of DENV particles residing
within the rough ER, and thus by definition being immature, was
possible. At 72 h post-infection, arrays of virions accumulating
within virion bags, and surrounded by rough ER membrane,
were readily visible in DMSO-treated samples. In agreement
with our earlier findings (Welsch et al., 2009), such structures
are usually close to the viral replication organelle composed of
virus-induced vesicles packets (VPs) that are ER membrane
invaginations into the ER lumen (Figure 6C). In drug-treated
samples, the total number of virion bags within infected cells
was drastically reduced, supporting the conclusion that intracel-
lular particles are shuttled more efficiently from the ER into the
secretory pathway (Figure 6D).
To corroborate this conclusion with an alternative approach,
we determined the intracellular distribution of DENV within the
secretory apparatus using biochemical separation of ER and
Golgi membranes through a Nycodenz step gradient (Figure 7A).
In drug-treated samples, higher amounts of the viral E protein
cofractionated in TGN46-positive fractions compared with
DMSO-treated control cells (Figure 7B). These fractions also
contained the most DENV infectivity (Figure 7C), while almost
no infectivity was present in Calnexin-positive ER fractions, con-
firming the proper separation of the intracellular membranes.
Altogether, these results point toward an altered intracellular
distribution of DENV particles upon FGFR signaling inhibition,
resulting in an increased load of infectious DENV particles in
the TGN compartment. Moreover, alteration of the intracellular
distribution seems to be specific for DENV particles, because
trafficking of small cargos, such as the vesicular stomatitis
virus G (VSV-G) protein, was not affected by modulation of the
FGFR signaling pathway (Figure S4).
FGFR Inhibition Increases Maturation of Intracellular
DENV Particles
Because DENV particles undergo a maturation cleavage of prM
within the TGN, we determined the amount of precursor prM and
mature M proteins present on the surface of secreted virions
upon FGFR or PI3K inhibitor treatment. Western blot analysis
revealed a prominent band at low molecular weight consistent
with mature M protein, in addition to a heavier protein reacting
with the M-specific antibody and corresponding to the prM
precursor (Figure 7D, left panel). Intensity of the lower band
increased in drug-treated samples compared with DMSO con-
trol cells, indicating enhanced prM cleavage. To confirm the
identity of these bands, immature DENV particles were gener-
ated by NH4Cl treatment of infected cells without or with subse-
quent in vitro cleavage by recombinant furin. In the NH4Cl-
treated sample, low levels of extracellular infectivity and the
absence of M confirmed the accumulation of predominantlyR. Cells were treated with compounds or DMSO as specified at the bottom.
and number of virion-associated RNAs.
pressing the different FGFR4 constructs.
d with Student’s t test (C) and one-way ANOVAwith Dunnett’s post hoc test (F).
Figure 6. FGFR4 Signaling Inhibition Increases prM Accumulation in the Golgi and Reduces Accumulation of Virions in an ER-Proximal
Compartment
(A) Colocalization between trans-Golgi networkmarker TGN46 and prM in Huh7 cells pretreatedwith DMSO or inhibitors of FGFR (PD173074) or PI3K (LY294002)
and infected for 48 h with DENV. Inhibitors were kept on the cells throughout the experiment. Scale bar, 10 mm.
(B) Quantification of the colocalization using Mander’s colocalization coefficients. Each dot represents one cell. Means and SD are shown. Data were analyzed
using Student’s t test.
(C) Cells treated with FGFR or PI3K inhibitors were infected with DENV for 72 h before processing for electron microscopy (EM) analysis. Scale bar, 1 mm. VP,
vesicles packet; VB, virion bag. Yellow boxes indicate areas magnified to the right of each panel.
(D) Quantification of the number of virion bags in 15 infected cells for each condition.
Means and SD are given. See also Figures S2–S4.
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Figure 7. FGFR4 Signaling Inhibition In-
creases prM Maturation Cleavage
(A) Extracts of Huh7 cells treated with inhibitors of
FGFR (PD173074) or PI3K (LY294002) and infected
for 48 hwith DENVwere fractionated to separate the
Golgi apparatus and ER membranes. The distribu-
tion of the indicated cellular and viral proteins was
analyzed by western blotting. Inhibitors were kept
on the cells throughout the experiment. The exper-
iment was repeated twice.
(B) Quantification of the bands from (A). Shaded
areas indicate TGN46 and calnexin distribution.
(C) Relative distribution of infectivity in the gradient
as determined by plaque assay. For each condition,
values were normalized to total infectivity.
(D) Enhanced cleavage of prM upon FGFR signaling
inhibition. Cells were infected with DENV and
treated with FGFR or PI3K inhibitors, treated with
20 mM NH4Cl, or treated with NH4Cl followed by
overnight digestion with recombinant furin. Virions
were purified, and prM and M were detected by
western blot using a prM-specific antibody (lower
panel). Quantifications of the signals are displayed
in the upper panel. Values were normalized to
DMSO-treated control cells (set to one). Bars
represent means and SD from 3 experiments. Data
were analyzed with one-way ANOVA with Dunnett’s
post hoc test (*p < 0.05). Red dots indicate virus
titers as determined by plaque assay. A represen-
tative experiment from three repetitions is shown.immature particles (Figure 7D, right panel). Upon furin treatment,
a restoration of particle infectivity was observed, concomitant
with the appearance of a lowmolecular weight protein comigrat-
ing with the one released from drug-treated cells (Figure 7D, right
panel), thus confirming its identity as M.
In conclusion, these results provide compelling evidence that
inhibition of the FGFR signaling pathway increases the specific
infectivity of DENV particles by enhanced maturation cleavage
of the prM protein in the viral E.
DISCUSSION
In this study, we screened the human kinome to identify host
kinases involved in DENV replication cycle. We could identify
39 kinases promoting or restricting DENV entry or replication.
The overlap between these candidates and previously reported
hit lists obtained after whole-genome screenings with other flavi-
viruses (Savidis et al., 2016; Kwon et al., 2014) is limited. This is
not unexpected, because differences in reagents and screening
setups have profound effects on experimental outcomes; there-
fore, overlaps between hit lists from different screenings is very
low in general (Savidis et al., 2016). For instance, a comparison
of our screening with the siRNA-based kinome screen by
Kwon and colleagues, who reported 30 kinases involved in2588 Cell Reports 27, 2579–2592, May 28, 2019DENV infection (Kwon et al., 2014), re-
vealed only 2 common hits: the feline sar-
coma oncogene (FES) tyrosine kinase
and the casein kinase 1 delta (CSNK1D).
However, while the FES kinase was identi-fied in both screenings as a DENV restriction factor, the CSNK1D
gene appears as a restriction factor in our screening but as a de-
pendency factor in the screening by Kwon et al. (2014). Although
the exact reason for this variance is not known, differences in
experimental conditions most likely account for this discrep-
ancy. In yet another screen employing small molecule inhibitors
of cellular tyrosine kinases to identify pathways exploited by
DENV during its life cycle, the Src family of kinases, and in partic-
ular the Fyn kinase, were found to play a role in viral replication
(Chu and Yang, 2007; de Wispelaere et al., 2013).
Among the kinases identified in the present study, we focused
our attention on FGFR4. Members of the FGFR family have been
previously identified as host factors involved in the replication of
several viruses. For instance, knockdown of FGFR4 was re-
ported to limit influenza virus entry and replication, while knock-
down of FGFR1 promoted its replication (Ko¨nig et al., 2010; Liu
et al., 2015). Moreover, ligand-induced stimulation of the FGFR
pathway inhibited replication of Coxsackievirus and vesicular
stomatitis virus (van Asten et al., 2018). Here we show that
several flaviviruses (all four DENV serotypes and two ZIKV line-
ages) are influenced by FGFR signaling. Inhibition of the
FGFR4 signaling pathway had a reciprocal effect by dampening
DENV replication and stimulating virus particlematuration, which
is mediated, at least partly, by increasing prM cleavage. Similar
results were obtained by inhibition of PI3K, arguing that the PI3K
arm of the FGFR4 pathway confers this effect. Activation of the
pathway by the natural ligand FGF19 or by overexpression of
constitutive active FGFR4 mutants markedly reduced virus
infectivity, thus confirming the specificity of the FGFR inhibitor
treatment. We observed a reduction in FGFR4 protein abun-
dance, together with a decrease in the phosphorylation levels
of the adaptor protein FRS2a, at late time points after infection,
whereas the amounts of the downstream kinase ERK1/2 were
not affected. Therefore, we conclude that FGFR4 signaling is
impaired during DENV infection specifically at the level of the
membrane receptor but does not affect all kinases of this
pathway. This observation might be counterintuitive, given
that FGFR4 was identified as a dependency factor promoting
DENV RNA replication. However, the inhibition of RNA replica-
tion induced by the inhibition of the FGFR signaling pathway is
gradually lost with extended time spans after infection. This
observation supports the assumption that FGFR promotes
DENV RNA replication at an early time point after infection,
e.g., to establish the viral replication organelle, while later,
when replication is at a steady state, the FGFR pathway is no
longer required for RNA amplification but instead is a disadvan-
tage for high-level production of infectious virus particles.
Our siRNA-based screen was designed to identify host factors
of relevance for viral entry and replication, because we used
high MOI infection and analyzed cells 24 h post-infection, i.e.,
conditions under which virus spread had not occurred. There-
fore, FGFR4 was identified as a dependency factor promoting
DENV RNA replication.
Ligand-induced dimerization activates the FGFR signaling
cascade that branches through four major signaling pathways:
PLCg-protein kinase C (PKC), signal transducer and activator
of transcription (STAT), RAS-MAPK, and PI3K-AKT. The latter
two rely on the docking protein FRS2a that constitutively associ-
ates with the membrane proximal region of FGFR and acts as a
docking platform for downstream effector proteins (Gotoh,
2008). Because phosphorylation of FRS2a decreases at late
time points after infection, one might assume that signaling inhi-
bition through the RAS-MAPK or the PI3K-AKT pathway might
influence DENV replication. Inhibition of PI3K with LY294002
recapitulated the effect observed upon FGFR blockade, i.e., a
reduction of viral replication and an increase of virus production.
In contrast, treatment with the ERK inhibitor U0126, previously
shown to inhibit the replication of DENV2 and other members
of the Flaviviridae family, such as yellow fever virus (YFV) and
hepatitis C virus (HCV) (Albarnaz et al., 2014; Zhao et al.,
2015), had no effect in our experimental setup.
Infection with DENV and Japanese encephalitis virus (JEV) or
expression of the West Nile virus (WNV) C protein was shown
to increase phosphorylation of the AKT kinase early during infec-
tion through a PI3K-dependent mechanism to inhibit apoptosis
(Lee et al., 2005; Urbanowski and Hobman, 2013). As a result,
inhibition of PI3K enhanced death of infected cells. Although
there is evidence that the PI3K-AKT axis promotes survival of
flavivirus-infected cells, the outcome of PI3K inhibition appears
to depend on the particular virus and cell culture system used.
For instance, treatment of mouse neuroblastoma cells or human
lung epithelial cells with LY294002 was reported to have no ef-fect on DENV and JEV replication or particle production (Lee
et al., 2005). In the case of WNV, an increase of infectivity was
observed upon PI3K inhibition with the same compound (Wang
et al., 2017). Althoughwe do not exclude a role of FGFR signaling
in DENV-induced cytopathic effects, our data suggest that the
inhibition of PI3K reduced DENV replication while increasing
specific infectivity. This phenotype was not observed upon inhi-
bition of the downstream effector kinase AKT (data not shown),
suggesting that PI3K enhances DENV infectivity by an AKT-inde-
pendent pathway. In any case, the increase in extracellular infec-
tivity as reported here was not due to a general augmentation of
the conventional secretory pathway, because release of the
Gaussia luciferase reporter was not affected. Enhanced infec-
tivity was also not due to an increase of virus particle assembly,
because the levels of DENV RNA and E released from cells were
unaltered by FGFR inhibitor treatment. Instead, the specific
infectivity of DENV particles was profoundly increased upon
FGFR pathway inhibition. In principle, two mechanisms could
account for enhanced infectivity. The first one is an alteration
of the lipid composition of virus particles, which has previously
been shown to affect virion stability and specific infectivity (Gull-
berg et al., 2018). Consistently, FGFR4 activation regulates
cholesterol synthesis (Tang et al., 2018), while signaling via
FGFR3 was shown to increase fatty acid synthesis in cancer
cells (Du et al., 2012). However, we found that stability of
DENV particles collected from FGFR inhibitor-treated cells was
not affected, arguing against an effect of the physical properties
of the viral lipid E. Still, alterations of the lipid composition of the
viral replication organellemight explain the reduction of viral RNA
replication observed upon inhibition of the FGFR signaling
pathway. Distinct lipids are likely required to create the energet-
ically favorable microenvironment necessary to induce ER
membrane curvature and formation of the invaginated vesicles
constituting the flaviviral replication organelle (Leier et al.,
2018). Lipidomic studies have highlighted an increase in ceram-
ides and other classes of sphingolipids upon flavivirus infection
(Martı´n-Acebes et al., 2014; Perera et al., 2012). In addition,
cholesterol has been shown to be essential for flaviviral replica-
tion (Leier et al., 2018). Thus, modulation of this pathway might
affect the availability of distinct lipids essential for the formation
of the viral replication organelle.
A secondmechanism that could explain the increased specific
infectivity of DENV particles upon FGFR pathway inhibition is
enhanced particle maturation. During flavivirus assembly, imma-
ture virions form by budding into the ER lumen and are secreted
via transport through the Golgi apparatus (Neufeldt et al., 2018).
Structural rearrangements of the viral surface glycoproteins,
uponexposure to the acidicmilieu of the TGN, allow for the recog-
nition of a cleavage motif in prM by the TGN-resident protease
furin (Neufeldt et al., 2018). The presence of a suboptimal furin
cleavage motif in DENV prM results in the production of highly
heterogeneous mosaic particles that display different grades
of maturation (Junjhon et al., 2008). Thus, variations in both
the prM sequence and the furin expression levels can affect par-
ticle maturation. We did not observe an increase in furin expres-
sion or enzymatic activity uponmodulation of the FGFR pathway.
However, we observed a higher amount of prM and E in the TGN
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biochemical fractionation and light microscopy. Therefore, it is
tempting to speculate that intracellular trafficking of DENV parti-
cles is altered upon FGFR signaling inhibition. Consistently, less
immaturevirionsweredetected in infectedanddrug-treatedcells,
as deduced from the lower number of virion bags, corresponding
todilatedERcisternae that contain regular arraysof virusparticles
(Welsch et al., 2009). While the exact role of these structures is
uncertain, virion bags might be an intracellular reservoir of imma-
tureassembledparticles tobedelivered to theTGN.Thisassump-
tion supports the hypothesis that the rate-limiting step of DENV
secretion is ER-to-Golgi trafficking and that this process might
be affected by FGFR signaling. However, the FGFR signaling
phenotype reportedhere is notdue to increasedparticle secretion
rate but rather is the result of enhanced prM cleavage, correlating
with prolonged accumulation of virions in the TGN and thus facil-
itating furin-mediated cleavage. Moreover, the influence of FGFR
on intracellular trafficking seems to be specific to DENV, because
transport of small cargo such as the VSV-G is not affected. Alter-
natively, FGFRsignaling has been reported to alterGolgimorpho-
genesis, aswell asmannose6-phosphate receptor traffickingand
recycling between the TGN and the plasma membrane (Anitei
et al., 2014). Therefore, FGFR inhibition might alter the trafficking
of furin to increase local abundance in those cellular compart-
ments containing immature DENV particles. However, a mecha-
nistic link between the alteration of virion trafficking and the
increase in prM maturation upon FGFR pathway inhibition needs
to be established. We cannot exclude other mechanisms that
might be responsible for increased particle infectivity, such as
modulation of the pH in organelles and vesicles of the secretory
pathway or altered particle assembly.
In conclusion, we report a novel role of FGFR signaling in
reciprocally regulating DENV RNA replication and virion matura-
tion. Given this opposing effect and the reduction of FGFR4
protein levels observed during the time course of infection, it is
tantalizing to speculate that the FGFR pathway might act as a
regulator, contributing to an early-late switch of the viral life
cycle. Early in infection, when FGFR4 levels are high, RNA repli-
cation is favored; in contrast, at a late stage of infection, when
FGFR4 levels and thus FGFR signaling are low, production of
infectious virus particles is favored by enhancing the maturation
cleavage of prM. The reciprocal role of FGFR4 reported here
illustrates the versatile strategies developed by viruses to exploit
in time and space the host machineries and signaling pathways
for the benefit of efficient propagation.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines and culture conditions
The mammalian cell lines Huh7 (Nakabayashi et al., 1982), HEK293T (Pear et al., 1993; DuBridge et al., 1987) and Vero clone E6
(ATCC CRL1586) were grown in Dulbecco’s modified minimal essential medium (DMEM; Invitrogen, Karlsruhe, Germany) supple-
mented with 2 mM L-glutamine, nonessential amino acids, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal calf serum in a
37C incubator with 5% CO2. The Aedes albopictus clone C6/36 (ATCC CRL1660) was maintained in minimal essential medium
(MEM; Invitrogen) supplemented with 10 mM HEPES [pH 7.4], 2 mM L-glutamine, nonessential amino acids, 100 U/ml penicillin,
100 mg/ml streptomycin, and 10% fetal calf serum at 28C. Origin and sex of all cell lines are stated in the Key Resources Table.
Viruses
The molecular clone of the DENV isolate 16681 has been reported previously (Fischl and Bartenschlager, 2013). The cloned genome
of the DENV isolate New Guinea C (NGC) was a kind gift from Dr. Andrew Davidson, University of Bristol, UK (Gualano et al., 1998).
The Zika virus strains MR766 and H/PF/2013 were obtained from the European Virus Archive (EVAg, France). All virus stocks were
prepared by amplification in C6/36 insect cells and virus titers were determined by plaque assay using Vero cells.
METHOD DETAILS
Plasmid constructions
Plasmids containing the full length DENV2 16681 sequence as well as the Renilla luciferase reporter virus and the sub-genomic
reporter replicon, both derived from the 16681 isolate, have been described elsewhere (Fischl and Bartenschlager, 2013). The
human FGFR4 gene was amplified from the human ORFeome collection and inserted into the lentiviral plasmid vector pWPI using
the Gateway recombination system (Invitrogen). To generate the constitutive active mutants, site directed mutagenesis was per-
formed using the Quickchange II system (Agilent, Santa Clara, CA) with the FGFR4 wild-type sequence as template and the following
primers: 50CGCCCGAGGCCAGGtgcACGGACATCATCCT30 and 50AGGATGATGTCCGTgcaCCTGGCCTCGGGCG30 for the Y367C
mutant and 50CATTGACTACTATAAGgagACCAGCAACGGCCGCC30 and 50GGCGGCCGTTGCTGGTctcCTTATAGTAGT
CAATG30 for the K645E mutant. In all constructs a hemagglutinin (HA) tag was added in-frame to the 50 end of the FGFR4 coding
sequence.
Primary siRNA Screening
The primary screening was performed by reverse transfection cell arrays with a human siRNA kinome library as described elsewhere
(Erfle et al., 2007; Willemsen et al., 2017; Reiss et al., 2011). This library targets all known and predicted 719 human kinases with three
individual siRNAs per gene (Silencer Human Kinase siRNA Library V3, AM80010V3; Ambion, ThermoFischer Scientific). Briefly, theCell Reports 27, 2579–2592.e1–e6, May 28, 2019 e3
siRNA-gelatin transfection solution was prepared in 384-well plates (Nalgene-Nunc) by mixing 5 mL of a 30 mM siRNA stock
solution with 3.5 mL of Lipofectamine 2000 (Invitrogen) and 3 mL Opti-MEM (Invitrogen) containing 0.4 M sucrose using an automated
liquid handler (MICROLAB STAR, Hamilton). After 20 min incubation at room temperature, 7.25 mL of 0.2% gelatine (G-9391,
Sigma-Aldrich) and 0.01% (v/v) fibronectin (Sigma-Aldrich) was added to themixture. This solutionwasarrayed onto single-well-cham-
bered Lab-Tek cover glass tissue culture dishes (Nalgene-Nunc) using a contact printer (ChipWriter ‘Compact’ and ‘Pro’, Bio-Rad lab-
oratories) with PTS600 solid pins (Point Technologies, Boulder, CO) resulting in a spot diameter of approximately 400 mmand a center-
to-center spot distance of 1.125 mm. The spot volume was approximately 4 nl. Lab-Tek chamber glasses were dried in plastic boxes
containing silica gel (Merck) at least overnight prior to use. After spotting, the first and last spot on the grid were marked with visual ink
on the outside of the glass to allow precise positioning of the microscope for image analysis of the exact spot area.
Huh7 cells were seeded onto the arrayed chamber slides at a density of 1.5x105 cells per chamber. After 48 h incubation, cells were
infected with the DENV2 NGC strain using aMOI of 5. The slides were harvested 24 h post-infection and processed for immunostain-
ing. After several times washing with PBS, cells were fixed with 2% paraformaldehyde (Sigma Aldrich) and permeabilized with 0.5%
Triton X-100 (Merk). Primary antibody (anti-E, diluted 1:100) and secondary antibody (anti-mouse Alexa Fluor 546, diluted 1:500)
(Invitrogen, A11030) were prepared in PBS, supplemented with 3% normal goat serum. Both antibodies were incubated for
45 min each and the staining procedure was repeated twice to improve the signal intensity. Nuclei were visualized by staining the
DNA with DAPI (4’,6’-diamidino-2-phenylindole dihydrochloride) (Molecular Probes, Karlsruhe, Germany). Slides were stored in
PBS containing 0.05% sodium azide until use. The images of individual siRNA spots were captured using an Olympus scanning
microscope (scan^ R, Olympus Biosystems) with a 10X objective. Acquired images were analyzed as described elsewhere (Matula
et al., 2009). For each experiment technical duplicates were performed and a total of six independent experiments were carried
out. Only siRNA spots containing more than 125 cells and less than 500 cells were included in the analysis. As additional quality
control for staining artifacts, all images were analyzed by eye and an additional 15% of the images and three experimental sets
were excluded from the final analysis. Statistical analysis of processed imaging data was carried out in R Version 2.8.0 (R Develop-
ment Core Team, http://www.R-project.org), using the Bioconductor packages RNAither (Rieber et al., 2009) and cellHTS (Livak and
Schmittgen, 2001). In brief, locally weighted scatterplot smoothing (LOWESS) was used to normalize the signal intensities for effects
of differing cell counts (Matula et al., 2009). Spatial effects within individual LabTeks were removed by B-score normalization (Rieber
et al., 2009) and the variability between plates was normalized by subtracting the plate median from each measurement and dividing
by the plate median absolute deviation. For statistical analysis, Z-scores were calculated from the mean signals over replicates and
the p-values were calculated for each siRNA using Student’s t test. Replicates were summarized using themean; furthermore, a t test
was carried out to determine whether siRNA effects differed significantly from zero. The mean score indicates the magnitude of an
effect, whereas the p value is a measure of the reproducibility. A knock-down was scored positive when its p value was < 0.05 and its
Z-score lower than1 in case of dependency factors or higher than +1 in case of restriction factors. This combination of p-value and
score allows the identification of genes with a relatively small, but consistent effect.
Validation siRNA screening
For validation of primary hits, reverse transfection of siRNAs in a 96-well plate format was used as described elsewhere (8). For each
of the 110 kinases three new siRNAs were purchased from Dharmacon (Horizon, UK). In brief, the transfection mix was prepared by
mixing 3 ml OptiMEM (containing 0.4 M sucrose) with 3.5 ml Lipofectamine 2000 (Invitrogen) and 5 ml of the respective siRNA (30mM
stock) in a 384-well plate using an automated liquid handler. After incubation for 20 min at room temperature, 7.25 ml of a 0.08% (w/v)
gelatin solution containing 0.01% (v/v) fibronectin were added to themixture and 17 ml of the source siRNA transfection solution were
transferred into a 96-well plate and combined with 850 ml of MilliQ water. Fifty-one ml of the transfection mixture were transferred into
each well of a 96-well plate (Greiner, cat. no. 655098) and plates were dried for 2.5 h at medium drying force in amultiwell Speed Vac.
Huh7 cells (5,000 cells per well) were seeded into siRNA-coated 96-well plates in a volume of 100 ml per well. Twenty four hours later
cells were inoculated with the DV-R2A Renilla luciferase reporter virus at an MOI of 0.5 and medium was exchanged 4 h later. Fourty
eight hours post infection, cells were harvested in 50 ml luciferase lysis buffer (1% (w/v) Triton X-100, 25 mM glycylglycine [pH 7.8],
15mMMgSO4, 4mMEGTA and 1mMDTT). Plates weremeasured using home-made substrates for Renilla luciferases as described
elsewhere (Fischl and Bartenschlager, 2013). The validation screening was performed twice in duplicates and statistically analyzed
as follows. Signal intensities normalized for cell count effects using locally weighted scatterplot smoothing, were normalized to the
negative controls by subtracting the median signal of the negative controls from each measurement and dividing by the median
absolute deviation of the negative controls. Replicates were summarized using the mean and hits were defined based on a score
threshold of ± 2.0 for at least one siRNA per gene.
Electroporation of DENV RNA
In vitro transcripts were generated as previously described (Chatel-Chaix et al., 2015) and used for electroporation of single cell sus-
pensions of either BHK21 or Huh7 cells that were generated by trypsinization. Cells were washed once with PBS and suspended in
cytomix containing 2mMATP and 5mM glutathione at a density of 1.53 107 or 1.03 107 cells per ml, respectively. Ten mg of in vitro-
transcribed RNA was mixed with 400 ml of cell suspension and cells were electroporated using a Gene Pulser system (Bio-Rad) in a
cuvette with a gap width of 0.4 cm (Bio-Rad) at 960 mF and 270 V. Cells were immediately transferred into complete DMEM and
seeded into appropriate formats.e4 Cell Reports 27, 2579–2592.e1–e6, May 28, 2019
Virus replication assays
For inhibition experiments, cells were pre-treated for 16 h with given compounds prior to infection. Inhibitors were present during
infection and all time thereafter. Cells plated in duplicate wells of 6-well plates were lysed at given time points in 350 ml lysis buffer
(1% Triton X-100, 25 mM glycylglycine, 15 mMMgSO4, 4 mM EGTA and 1 mMDTT [pH 7.8]) using repetitive freeze-thaw cycles. For
each well, two times 100 ml lysate was mixed with 360 ml assay buffer (25 mM glycylglycine, 15 mMMgSO4, 4 mM EGTA, 1 mM DTT,
2 mM ATP and 15 mM K2PO4, [pH 7.8]) and, after addition of 200 ml of a luciferin solution (200 mM luciferin, 25 mM glycylglycine
[pH 8.0]), measured for 20 s in a luminometer (Lumat LB9507; Berthold, Freiburg, Germany). Replication kinetics were determined
by normalizing the relative light units (RLU) measured at different time points after transfection to the 4 h value that reflects translation
from the input RNA and thus transfection efficiency.
RNA quantification by RT-qPCR
Total cellular RNA from around 5 3 105 virus-infected cells was isolated using the Nucleo Spin RNAII kit (Macherey-Nagel, D€uren,
Germany) as recommended by the manufacturer. cDNA was generated using the High Capacity cDNA RT kit (4368814, Applied
Biosystems, ThermoFisher scientific). Quantitative PCR was done using an ABI PRISM 7000 sequence detector system (Applied
Biosystems, Foster City, CA). For each primer set, reactions were conducted in triplicate using the Green Dye RT-PCR master
mix (PJK GmbH, Hilden, Germany) according to the instructions of the manufacturer and the following primers: forward - 50TTG
AGTAAACTGTGCAGCCTGTAGCTC30 and reverse - 50GGGTCTCCTCTAACCTCTAGTCCT30 (DENV); forward - 50GAAGGTGAAG
GTCGGAGT30 and reverse - 50GGGTCTCCTCTAACCTCTAGTCCT30 (GAPDH). The total volume of the reaction mix was 15 ml and
reactions were performed in three stages: stage 1, 15 min at 95C; stage 2, 40 cycles with each 15 s at 95C and 60 s at 60C. Quan-
tities of DENV RNA were calculated by using serial dilutions of known amounts of DENV in vitro transcripts that were processed in
parallel. For cellular genes, the DDCT method (5) was used to calculate the relative expression levels.
Indirect immunofluorescence
Huh7 cells were seeded onto glass coverslips in 24-well plates (6x104 cells/well). After 16 h, cells were treated with different chemical
inhibitors as specified in the results section, and 8 h later infected with DENV2 for one hour in the presence of the inhibitors. At
different time points post-infection, cells were fixed with 4% paraformaldehyde (Applichem GmbH, Darmstadt, Germany) and
permeabilized with 0.5% (v/v) Triton X-100 in PBS. Primary staining was done by 45 min incubation with primary antibodies
diluted in PBS containing 10%normal goat serum. After several washeswith PBS, secondary staining was done by 45min incubation
with an Alexa-conjugated secondary antibody, diluted 1:1,000 in PBS containing 10% goat serum. Nuclear DNA was stained
with DAPI (Molecular Probes). Samples were mounted onto glass slides with Fluoromount G (Southern Biotechnology Associates,
Birmingham, USA) and images were acquired using a Nikon Eclipse Ti spinning disc confocal laser microscope or a Leica
confocal SP8. Images were processed and quantified using the ImageJ software package (National Institute of Health, Bethesda,
MD, USA).
Lentivirus production and FGFR4 overexpression
For lentivirus production, 293T cells were transfected with the packaging plasmids pCMV-Gag-Pol and pMD2-VSV-G (kind gifts from
Didier Trono, EPFL, Lausanne, Switzerland) together with the pWPI vector coding for the different FGFR4 proteins by using polye-
thylenimine (Polysciences Inc.). Two days post-transfection, lentivirus-containing supernatant was harvested and filtered through a
0.45 mm pore-size filter. Virus titers were determined by transduction of HeLa cells using serial dilutions of the lentivirus preparation
and selection with 1 mg/ml puromycin. Cells were fixed five days later and stained with 1% crystal violet/10% ethanol for 30min. After
extensive rinsing with water, cell colonies were counted and titers were calculated. For FGFR4 mutants overexpression, Huh7 cells
were transduced using an MOI of 5 for three days prior to infection with wild-type DENV (MOI = 0.1) or DV-R2A (MOI = 1).
Generation of trans-complemented DENV particles
Production of trans-complemented DENV particles (DENVTCP) was performed as previously described (Scaturro et al., 2014). Briefly,
10 mg of in-vitro transcribed DV-R2A subgenomic RNA were electroporated into 293T cells. After 24 h, cells were transduced with
lentiviruses encoding for prM-E and capsid. Temperature was shifted to 33C, supernatants were collected at day 4 and day 6
post-transduction, pooled and filtered through a 0.44 mm pore-size filter.
Generation of furin KO cells
To have a cell line that could be used as negative control in our furin assays, we generated furin knock-out Huh7 cells. The guide RNA
sequence for furin was taken from a public database (GeCKO library, (Sanjana et al., 2014)). Complementary synthetic oligonucle-
otides of the desired sequence (50CGTACCAGGTACCACTGCTG03) were annealed and inserted into the lentiCRISPRv2 plasmid
containing a puromycin resistance gene. Lentiviruses were generated as described above and Huh7 cells were transduced using
an MOI of 5. Selection was started 24 h after transduction with 3 mg/ml puromycin. Drug resistant cell pools were expanded and furin
knock-out was validated by western blot.Cell Reports 27, 2579–2592.e1–e6, May 28, 2019 e5
Electron microscopy
Huh7 cells were treated for 16 h with FGFR and PI3K inhibitors (PD173074 and Ly294002, respectively) or DMSO, andmock-infected
or infected with DENV in the presence of the inhibitors. Cells were fixed 72 h later with EM fixative (2.5% glutaraldehyde in 50 mM
cacodylate, 50 mM KCl, 2.6 mM CaCl2, 2.6 mM MgCl2, 2% sucrose) for at least one hour at room temperature and embedded in
epoxy resin as previously described (Cortese et al., 2017). Samples were examined with a TEM Zeiss 10C electron microscope
(Carl Zeiss, Oberkochen) at 80 kV and images analyzed using the ImageJ software package.
Cell fractionation
All steps of the fractionation procedure were carried at 4C. Huh7 cells seeded into 15 cm-diameter dishes (1.5x 107 cells/dish) were
left untreated or treated with the FGFR4 inhibitor PD173074 (0.6 mM) or the PI3K inhibitor LY294002 (10 mM), and infected with DENV.
Forty-eight hours later, cells were scraped into ice-cold PBS, and centrifuged for 10 min at 700xg. Cell pellets were gently resus-
pended in 1 mL HOP buffer (50 mM Tris-HCl [pH 7.5], 120 mM NaCl, 30 mM KCl, 3 mM EDTA) and dissociated as previously
described (Ba¨r et al., 2013). Nuclei were separated by centrifugation at 1000xg for 5 min, clarified supernatants were adjusted to
2 mL and centrifuged through a Nycodenz step-gradient (2 mL 30%, 1.33 mL 20%, 1.33 mL 15%, 1.33 mL 10%, 1.33 mL 7.5%,
1.33 mL 5%, 1.33 mL 2.5% (w/v) Nycodenz in HOP) at 33000xg for 15 min in a SW40 rotor (Beckman, Pasadena, CA). Eight fractions
of 1.33 mL were collected from the top of the gradient and analyzed by western-blot or plaque assay.
Furin cleavage assay
Purified immature virus particles were treated with furin as described earlier (Yu et al., 2009). Briefly, Huh7 cells grown in 10 cm-
diameter dishes were infected with DENV (MOI = 3). After 24 h, medium was replaced by complete DMEM containing 20 mM
NH4Cl. Supernatants were harvested 48 h post-infection and virus particles were concentrated by ultracentrifugation through a
20% sucrose cushion in NTE buffer (100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 1 mM EDTA) for 4 h at 24,000 rpm in a SW32 Ti rotor
(Beckman) at 4C. Virus containing pellets were resuspended in NTE buffer. Samples were mixed with an equal volume of 50 mM
2-(N-morpholino)ethanesulfonic acid (MES) to adjust the pH to 6.0 and 4 units of purified Furin (New England Biolabs, P8077) in a
final concentration of 3 mM CaCl2. After 16 h incubation at 30
C, the reaction was terminated by neutralization of the pH using
one volume of 100 mM Tris [pH 8.0] and 120 mM NaCl.
Furin enzyme activity assay
Huh7 cells seeded in 96 well black plate, were pre-treated for 16 h with compounds and infected with DENV2 (MOI = 0.1) or mock
infected. After 72 h, cells were washed in PBS three times and incubated for 4 h in assay buffer (DMEM without phenol-red, 100 mM
furin fluorogenic substrate BOC-RVRR-AMC, 0.25% Triton X-100). After cell lysis, samples were diluted 1:4 in PBS and incubated for
additional 24 h at room temperature. Fluorescence was measured using 380 nm for excitation and 460 nm emission recording. Data
were normalized to cell density (calculated by measurement of ATP levels on a culture plate treated in parallel) and normalized to
values obtained with DMSO treated control cells. Furin knock-out cells were used as positive control to confirm the specificity of
the furin assay.
VSV-G trafficking assay
Huh7 cells were transfected with the VSV-G_ts045_GFP construct. After 6 h medium was replaced by imaging medium containing
0.6 mMPD173074 or DMSOand temperature was increased to 40C. Two hours before imaging, 100 mMcycloheximidewas added to
the cells. Cells were imaged 24 h post-transfection at 32Cwith a confocal spinning disc microscope. For each cell, a single confocal
slice was collected every 5 min. For each time point, the fluorescence intensity in a region of interest surrounding the perinuclear area
was calculated and normalized to the intensity at time point 0.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed with the GraphPad Prism 5.0 software package (LaJolla, CA, USA). To assess statistical
significance, both the two-tailed paired Student’s t test with Bonferroni correction for multiple samples comparison or one-way
ANOVA and Dunnett’s post hoc test analysis were used. Datasets were considered significantly different if the P value was less
than 0.05. For each experiment, the statistical analysis performed and the sample sizes are listed in figure legends.e6 Cell Reports 27, 2579–2592.e1–e6, May 28, 2019
